Revelation Biosciences, Inc.
REVB
$3.40
$0.061.80%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.20% | 23.33% | 25.17% | -17.79% | -28.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.22% | 59.59% | 51.56% | -20.32% | -44.09% |
| Operating Income | -13.22% | -59.59% | -51.56% | 20.32% | 44.09% |
| Income Before Tax | -1,873.22% | -781.72% | -560.43% | 98.89% | 106.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,873.22% | -781.72% | -560.43% | 98.89% | 106.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,873.22% | -781.72% | -560.43% | 98.89% | 106.49% |
| EBIT | -13.22% | -59.59% | -51.56% | 20.32% | 44.09% |
| EBITDA | -13.24% | -59.82% | -51.78% | 20.37% | 44.18% |
| EPS Basic | 35.00% | -63.23% | -165.31% | -481.46% | -- |
| Normalized Basic EPS | 19.33% | -138.61% | -430.62% | -381.46% | -- |
| EPS Diluted | 35.04% | -63.08% | -164.90% | -480.72% | -- |
| Normalized Diluted EPS | 19.33% | -138.61% | -430.62% | -381.46% | -- |
| Average Basic Shares Outstanding | 652.23% | 564.38% | 672.19% | 221.19% | -- |
| Average Diluted Shares Outstanding | 469.61% | 344.86% | 286.09% | 321.19% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
